Table 4 

MTHFR C677T and breast cancer survival 

Personyears^{1} 
# events^{2} 
HR (95% CI)^{3} 
pvalue 



C677T genotype (n = 198) 

C/C 
1 

C/T or T/T 
873 
46 
0.65 (0.31–1.35) 
0.25 
ERnegative (n = 84) 

C/C 
1 

C/T or T/T 
352 
29 
0.36 (0.12–1.04) 
0.06 
ERpositive (n = 114) 

C/C 
1 

C/T or T/T 
521 
17 
1.12 (0.35–3.59) 
0.82 
AfricanAmerican (n = 121) 

C/C 
1 

C/T or T/T 
520 
29 
0.12 (0.02–0.92) 
0.04 
Caucasian (n = 77) 

C/C 
1 

C/T or T/T 
352 
17 
1.89 (0.57–6.32) 
0.3 
No Chemotherapy (n = 81) 

C/C 
1 

C/T or T/T 
394 
13 
0.88 (0.21–3.74) 
0.87 
Chemotherapy (n = 117) 

C/C 
1 

C/T or T/T 
479 
33 
0.55 (0.22–1.34) 
0.19 


^{1 }Time at risk in personyears. ^{2 }Number of deaths due to breast cancer. ^{3 }Cox ProportionalHazards regression with adjustments for age at diagnosis, race, A1298C, BMI, estrogen receptor, TNM stage, and chemotherapy. 

Martin et al. BMC Cancer 2006 6:257 doi:10.1186/147124076257 